<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="96921">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01843023</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DA033391-01A1</org_study_id>
    <secondary_id>R01DA033391</secondary_id>
    <nct_id>NCT01843023</nct_id>
  </id_info>
  <brief_title>Extended Release Naltrexone for Opioid-Dependent Youth</brief_title>
  <official_title>Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Friends Research Institute, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Friends Research Institute, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare 6-month treatment outcomes for 15-21 year old
      opioid-dependent youth receiving extended release naltrexone (XR-NTX) v. Treatment as Usual
      (TAU).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This proposed study is a 6-month, two-group randomized clinical trial of XR-NTX v. TAU for
      340 opioid-dependent youth ages 15-21. The study will be conducted at Mountain Manor
      Treatment Center, a community drug treatment program in Baltimore. TAU will consist of
      buprenorphine treatment of opioid withdrawal followed by counseling with or without
      continued buprenorphine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid use at 6 month follow-up</measure>
    <time_frame>6 months</time_frame>
    <description>To determine the relative effectiveness of XR-NTX compared to TAU for opioid-dependent youth in terms of opioid use at 6-months post-treatment entry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment retention</measure>
    <time_frame>6 months</time_frame>
    <description>To determine the relative effectiveness of XR-NTX compared to TAU for opioid-dependent youth in terms of days in treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monetized Economic Form 90 scores as a function of treatment costs</measure>
    <time_frame>6 months</time_frame>
    <description>The cost-effectiveness will be assessed using the Economic Form 90 to collect data on economic outcomes of health utilization, crime, and employment/school enrollment status at each assessment point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV sex risk behaviors</measure>
    <time_frame>6 months</time_frame>
    <description>To examine the impact of XR-NTX on HIV sex-risk behaviors at 6 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Drug Dependence</condition>
  <arm_group>
    <arm_group_label>Extended Release Naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomly assigned to XR-NTX who do not have opioid withdrawal signs or symptoms within 4 hours of administration of the 25 mg oral dose naltrexone will be given an intramuscular injection of XR-NTX [VivitrolÂ®] at a dose of 4cc (380mg of naltrexone)] and will subsequently have the same dose administered to alternating sides of the buttocks every four weeks for up to 6 months. All participants will also receive psychosocial treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment as Usual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants randomly assigned to TAU will participate in the standard youth opioid program at the treatment center which includes either buprenorphine taper or ongoing buprenorphine treatment during the 6 months of the study for as long as they and their physicians think is appropriate. The general target dose will be 12-20 mg buprenorphine per day. All participants in TAU will receive psychosocial treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extended Release Naltrexone</intervention_name>
    <description>naltrexone for extended release injectable suspension</description>
    <arm_group_label>Extended Release Naltrexone</arm_group_label>
    <other_name>Vivitrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychosocial Treatment</intervention_name>
    <description>Psychosocial treatment will consist of group and individual drug abuse counseling at MMTC and in the community.</description>
    <arm_group_label>Extended Release Naltrexone</arm_group_label>
    <arm_group_label>Treatment as Usual</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Participants assigned to TAU will receive buprenorphine for opioid withdrawal and will either be tapered off the medication or will remain on it for individualized lengths of time during the six month study.</description>
    <arm_group_label>Treatment as Usual</arm_group_label>
    <other_name>Suboxone</other_name>
    <other_name>Subutex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets Diagnostic and Statistical Manual-IV criteria for opioid dependence,
             physiologic subtype;

          -  Within 3 days of admission to MMTC;

          -  Age between 15 and 21, inclusive;

          -  Able and willing to provide informed consent to be randomly assigned to XR- NTX or
             TAU; and for participants under 18 years of age, parental or guardian consent and
             participant assent.

        Exclusion Criteria:

          -  Liver function test levels (Alanine Transaminase, Aspartate Transaminase) four times
             greater than normal;

          -  Unstable medical or psychiatric illness (e.g., schizophrenia) that might make
             participation hazardous;

          -  History of serious suicide attempt in the past 6 months;

          -  History of allergic reaction to naloxone, and/or naltrexone;

          -  Current chronic pain condition for which opioids are deemed necessary for ongoing
             care;

          -  blood coagulation disorder (e.g., hemophilia);

          -  Body Mass Index &gt; 40;

          -  If female, pregnant, lactating, unwilling or unable (due to parental objection) to
             use FDA-approved contraceptive methods;

          -  meeting DSM-IV criteria for benzodiazepine dependence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shannon G Mitchell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Friends Research Institute, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shannon G Mitchell, PhD</last_name>
    <phone>410-837-3977</phone>
    <phone_ext>238</phone_ext>
    <email>smitchell@friendsresearch.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert P Schwartz, MD</last_name>
    <phone>410-837-3977</phone>
    <phone_ext>276</phone_ext>
    <email>rschwartz@friendsresearch.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Friends Research Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon G Mitchell, PhD</last_name>
      <phone>410-837-3977</phone>
      <phone_ext>238</phone_ext>
      <email>smitchell@friendsresearch.org</email>
    </contact>
    <contact_backup>
      <last_name>Robert P Schwartz, MD</last_name>
      <phone>410-837-3977</phone>
      <phone_ext>276</phone_ext>
      <email>rschwartz@friendsresearch.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mountain Manor Treatment Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc J Fishman, MD</last_name>
      <phone>410-233-1400</phone>
      <email>mjfishman@comcast.net</email>
    </contact>
    <investigator>
      <last_name>Marc J Fishman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 29, 2016</lastchanged_date>
  <firstreceived_date>April 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>opioid dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
